<p>WAVE 生命科学有限公司（NASDAQ:WVE - 获取免费报告）董事 Heidi Wagner 于 12 月 8 日星期一出售了 14,000 股该公司的股票，交易价格为每股 13.50 美元，总价值为 189,000.00 美元。交易完成后，该董事直接持有公司 44,930 股股票，估值约为 606,555 美元。此次交易使其持股减少了 23.76%。该交易已在向 SEC 提交的文件中披露，相关文件可在 SEC 网站上查阅。</p>
<p>获取 <strong>WAVE 生命科学</strong> 的提醒：</p>
<h2>WAVE 生命科学股票下跌 5.1%</h2>
<ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p>在周三的午盘交易中，NASDAQ WVE 的股票下跌了 1.08 美元，跌至 20.23 美元。该公司交易了 17,639,147 股，相比其平均交易量 11,192,010 股。该股票的 50 日简单移动平均为 8.27 美元，200 日简单移动平均为 7.90 美元。WAVE 生命科学有限公司的 1 年最低价为 5.28 美元，1 年最高价为 21.73 美元。该公司的市值为 33.8 亿美元，市盈率为-26.97，贝塔值为-1.72。</p>
<p>WAVE 生命科学（NASDAQ:WVE - 获取免费报告）最近于 11 月 10 日星期一公布了季度财报。该公司报告每股收益（EPS）为-0.32 美元，低于市场共识预期的-0.30 美元，差额为-0.02 美元。该季度的收入为 761 万美元，而分析师预期为 985 万美元。WAVE 生命科学的净利润率为-111.64%，股本回报率为-75.61%。分析师预计 WAVE 生命科学有限公司本财年的每股收益将为-1.14 美元。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>WAVE 生命科学因历史性 RNA 编辑成功而飙升 70%</li>
</ul>
<p>一些研究分析师最近对 WVE 股票发表了看法。加拿大皇家银行将 WAVE 生命科学的评级从 “行业表现” 上调至 “跑赢大盘”，并在周一的报告中将其目标价从 9.00 美元上调至 27.00 美元。B. Riley 在 9 月 4 日星期四的研究报告中重申了对 WAVE 生命科学股票的 “买入” 评级。Canaccord Genuity Group 在周一的研究报告中将 WAVE 生命科学的目标价从 19.00 美元上调至 40.00 美元，并给予该股票 “买入” 评级。富国银行在周二的研究报告中将 WAVE 生命科学的目标价从 16.00 美元上调至 29.00 美元，并给予该股票 “增持” 评级。最后，摩根士丹利在周一的研究报告中设定了 WAVE 生命科学的目标价为 28.00 美元。十二位投资分析师对该股票给予了 “买入” 评级，一位分析师对该公司给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 27.46 美元。</p>
<p><strong>获取我们对 WVE 的最新分析</strong></p>
<h2>机构资金流入和流出</h2>
<ul>
<li>Sarepta Therapeutics Inc.：为什么它是一个崛起的基因治疗明星</li>
</ul>
<p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Adage Capital Partners GP L.L.C.在第二季度将其在 WAVE 生命科学的持股增加了 20.0%。Adage Capital Partners GP L.L.C.目前持有 15,016,500 股该公司的股票，价值 97,607,000 美元，此前在该期间内又增持了 2,500,000 股。683 Capital Management LLC 在第二季度将其在 WAVE 生命科学的持股增加了 4.5%。683 Capital Management LLC 目前持有 4,100,000 股该公司的股票，价值 26,650,000 美元，此前在上个季度又购买了 175,000 股。Federated Hermes Inc.在第三季度将其在 WAVE 生命科学的持股增加了 678,144.7%。Federated Hermes Inc.目前持有 3,750,693 股该公司的股票，价值 27,455,000 美元，此前在上个季度又购买了 3,750,140 股。Loomis Sayles &amp; Co. L P 在第二季度将其在 WAVE 生命科学的持股增加了 35.3%。Loomis Sayles &amp; Co. L P 目前持有 3,295,700 股该公司的股票，价值 21,422,000 美元，此前在该期间内又购买了 859,160 股。最后，Emerald Advisers LLC 在第二季度将其在 WAVE 生命科学的持股增加了 3.9%。Emerald Advisers LLC 目前持有 3,257,119 股该公司的股票，价值 21,171,000 美元，此前在上个季度又购买了 123,561 股。机构投资者和对冲基金持有该公司 89.73% 的股份。</p>
<h2>WAVE 生命科学公司简介</h2>
<p>（获取免费报告）</p>
<p>WAVE 生命科学有限公司是一家临床阶段的生物技术公司，通过 PRISM 发现和药物开发平台设计、开发和商业化核糖核酸（RNA）药物。该公司的 RNA 药物平台 PRISM 结合了多种模式、化学创新和对人类遗传学的深刻洞察，以提供治疗稀有和常见疾病的科学突破。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 WAVE 生命科学更好</li>
<li>使用 MarketBeat 股票拆分计算器</li>
<li>市场动量：3 只有望大幅突破的股票</li>
<li>投资于便士股票需要了解的事项</li>
<li>Casey’s General Stores 将继续上涨的 3 个理由</li>
<li>什么是股票市场指数以及如何使用它们？</li>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 WAVE 生命科学吗？</h2>
<p>在你考虑 WAVE 生命科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议他们在更广泛的市场注意到之前就买入……而 WAVE 生命科学并不在名单上。</p>
<p>虽然 WAVE 生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

WAVE生命科学

<p>WAVE 生命科学的董事 Heidi Wagner 以每股 13.50 美元的价格出售了 14,000 股，总计 189,000 美元。这次出售使她的持股减少了 23.76%，剩余持有 44,930 股，价值 606,555 美元。该交易已在 SEC 备案中披露。WAVE 生命科学的股票价格波动，最近的价格为 20.23 美元，市值为 33.8 亿美元。分析师对该股票给予了 “适度买入” 的评级，普遍目标价为 27.46 美元</p>

<p>WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) Director Heidi Wagner sold 14,000 shares of the business's stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.50, for a total value of $189,000.00. Following the completion of the transaction, the director directly owned 44,930 shares in the company, valued at approximately $606,555. The trade was a 23.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.</p>
<div class="lb-trans"><p>WAVE 生命科学有限公司（NASDAQ:WVE - 获取免费报告）董事 Heidi Wagner 于 12 月 8 日星期一出售了 14,000 股该公司的股票，交易价格为每股 13.50 美元，总价值为 189,000.00 美元。交易完成后，该董事直接持有公司 44,930 股股票，估值约为 606,555 美元。此次交易使其持股减少了 23.76%。该交易已在向 SEC 提交的文件中披露，相关文件可在 SEC 网站上查阅。</p>
</div><p>Get <strong>WAVE Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>WAVE 生命科学</strong> 的提醒：</p>
</div><h2>WAVE Life Sciences Stock Down 5.1%</h2>
<div class="lb-trans"><h2>WAVE 生命科学股票下跌 5.1%</h2>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p>Shares of NASDAQ WVE traded down $1.08 during mid-day trading on Wednesday, hitting $20.23. 17,639,147 shares of the company were exchanged, compared to its average volume of 11,192,010. The stock has a 50 day simple moving average of $8.27 and a 200-day simple moving average of $7.90. WAVE Life Sciences Ltd. has a 1-year low of $5.28 and a 1-year high of $21.73. The firm has a market cap of $3.38 billion, a price-to-earnings ratio of -26.97 and a beta of -1.72.</p>
<div class="lb-trans"><p>在周三的午盘交易中，NASDAQ WVE 的股票下跌了 1.08 美元，跌至 20.23 美元。该公司交易了 17,639,147 股，相比其平均交易量 11,192,010 股。该股票的 50 日简单移动平均为 8.27 美元，200 日简单移动平均为 7.90 美元。WAVE 生命科学有限公司的 1 年最低价为 5.28 美元，1 年最高价为 21.73 美元。该公司的市值为 33.8 亿美元，市盈率为-26.97，贝塔值为-1.72。</p>
</div><p>WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). The firm had revenue of $7.61 million during the quarter, compared to analyst estimates of $9.85 million. WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. Analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>WAVE 生命科学（NASDAQ:WVE - 获取免费报告）最近于 11 月 10 日星期一公布了季度财报。该公司报告每股收益（EPS）为-0.32 美元，低于市场共识预期的-0.30 美元，差额为-0.02 美元。该季度的收入为 761 万美元，而分析师预期为 985 万美元。WAVE 生命科学的净利润率为-111.64%，股本回报率为-75.61%。分析师预计 WAVE 生命科学有限公司本财年的每股收益将为-1.14 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Wave Life Sciences Rockets 70% on Historic RNA Editing Success</li>
</ul>
<div class="lb-trans"><ul>
<li>WAVE 生命科学因历史性 RNA 编辑成功而飙升 70%</li>
</ul>
</div><p>A number of research analysts recently weighed in on WVE shares. Royal Bank Of Canada raised WAVE Life Sciences from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating and upped their price objective for the stock from $9.00 to $27.00 in a report on Monday. B. Riley reaffirmed a &#34;buy&#34; rating on shares of WAVE Life Sciences in a research note on Thursday, September 4th. Canaccord Genuity Group raised their price target on shares of WAVE Life Sciences from $19.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday. Wells Fargo &amp; Company lifted their target price on shares of WAVE Life Sciences from $16.00 to $29.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday. Finally, Morgan Stanley set a $28.00 price target on WAVE Life Sciences in a research note on Monday. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $27.46.</p>
<div class="lb-trans"><p>一些研究分析师最近对 WVE 股票发表了看法。加拿大皇家银行将 WAVE 生命科学的评级从 “行业表现” 上调至 “跑赢大盘”，并在周一的报告中将其目标价从 9.00 美元上调至 27.00 美元。B. Riley 在 9 月 4 日星期四的研究报告中重申了对 WAVE 生命科学股票的 “买入” 评级。Canaccord Genuity Group 在周一的研究报告中将 WAVE 生命科学的目标价从 19.00 美元上调至 40.00 美元，并给予该股票 “买入” 评级。富国银行在周二的研究报告中将 WAVE 生命科学的目标价从 16.00 美元上调至 29.00 美元，并给予该股票 “增持” 评级。最后，摩根士丹利在周一的研究报告中设定了 WAVE 生命科学的目标价为 28.00 美元。十二位投资分析师对该股票给予了 “买入” 评级，一位分析师对该公司给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 27.46 美元。</p>
</div><p><strong>Get Our Latest Analysis on WVE</strong></p>
<div class="lb-trans"><p><strong>获取我们对 WVE 的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Sarepta Therapeutics Inc.: Why it's a rising gene therapy star</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta Therapeutics Inc.：为什么它是一个崛起的基因治疗明星</li>
</ul>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. grew its position in WAVE Life Sciences by 20.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company's stock valued at $97,607,000 after acquiring an additional 2,500,000 shares during the period. 683 Capital Management LLC lifted its stake in shares of WAVE Life Sciences by 4.5% in the 2nd quarter. 683 Capital Management LLC now owns 4,100,000 shares of the company's stock valued at $26,650,000 after purchasing an additional 175,000 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of WAVE Life Sciences by 678,144.7% in the 3rd quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company's stock valued at $27,455,000 after purchasing an additional 3,750,140 shares in the last quarter. Loomis Sayles &amp; Co. L P grew its holdings in shares of WAVE Life Sciences by 35.3% during the 2nd quarter. Loomis Sayles &amp; Co. L P now owns 3,295,700 shares of the company's stock worth $21,422,000 after purchasing an additional 859,160 shares during the period. Finally, Emerald Advisers LLC increased its position in WAVE Life Sciences by 3.9% during the 2nd quarter. Emerald Advisers LLC now owns 3,257,119 shares of the company's stock worth $21,171,000 after purchasing an additional 123,561 shares in the last quarter. Institutional investors and hedge funds own 89.73% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Adage Capital Partners GP L.L.C.在第二季度将其在 WAVE 生命科学的持股增加了 20.0%。Adage Capital Partners GP L.L.C.目前持有 15,016,500 股该公司的股票，价值 97,607,000 美元，此前在该期间内又增持了 2,500,000 股。683 Capital Management LLC 在第二季度将其在 WAVE 生命科学的持股增加了 4.5%。683 Capital Management LLC 目前持有 4,100,000 股该公司的股票，价值 26,650,000 美元，此前在上个季度又购买了 175,000 股。Federated Hermes Inc.在第三季度将其在 WAVE 生命科学的持股增加了 678,144.7%。Federated Hermes Inc.目前持有 3,750,693 股该公司的股票，价值 27,455,000 美元，此前在上个季度又购买了 3,750,140 股。Loomis Sayles &amp; Co. L P 在第二季度将其在 WAVE 生命科学的持股增加了 35.3%。Loomis Sayles &amp; Co. L P 目前持有 3,295,700 股该公司的股票，价值 21,422,000 美元，此前在该期间内又购买了 859,160 股。最后，Emerald Advisers LLC 在第二季度将其在 WAVE 生命科学的持股增加了 3.9%。Emerald Advisers LLC 目前持有 3,257,119 股该公司的股票，价值 21,171,000 美元，此前在上个季度又购买了 123,561 股。机构投资者和对冲基金持有该公司 89.73% 的股份。</p>
</div><h2>WAVE Life Sciences Company Profile</h2>
<div class="lb-trans"><h2>WAVE 生命科学公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.</p>
<div class="lb-trans"><p>WAVE 生命科学有限公司是一家临床阶段的生物技术公司，通过 PRISM 发现和药物开发平台设计、开发和商业化核糖核酸（RNA）药物。该公司的 RNA 药物平台 PRISM 结合了多种模式、化学创新和对人类遗传学的深刻洞察，以提供治疗稀有和常见疾病的科学突破。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than WAVE Life Sciences</li>
<li>Using the MarketBeat Stock Split Calculator</li>
<li>Market Momentum: 3 Stocks Poised for Major Breakouts</li>
<li>What to Know About Investing in Penny Stocks</li>
<li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 WAVE 生命科学更好</li>
<li>使用 MarketBeat 股票拆分计算器</li>
<li>市场动量：3 只有望大幅突破的股票</li>
<li>投资于便士股票需要了解的事项</li>
<li>Casey’s General Stores 将继续上涨的 3 个理由</li>
<li>什么是股票市场指数以及如何使用它们？</li>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V1ZF" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=WVE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in WAVE Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 WAVE 生命科学吗？</h2>
</div><p>Before you consider WAVE Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 WAVE 生命科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议他们在更广泛的市场注意到之前就买入……而 WAVE 生命科学并不在名单上。</p>
</div><p>While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 WAVE 生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内部人士出售：WAVE 生命科学（NASDAQ:WVE）董事出售了 14,000 股股票